BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CFO Aaron Rosenberg sold 1,190 shares of BeOne Medicines stock in a transaction on Friday, August 1st. The shares were sold at an average price of $290.47, for a total transaction of $345,659.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
BeOne Medicines Price Performance
ONC traded down $10.11 during trading on Friday, hitting $288.18. 423,056 shares of the stock traded hands, compared to its average volume of 462,618. The company has a 50-day moving average price of $269.66. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $170.99 and a 12-month high of $313.29. The company has a market cap of $31.58 billion, a price-to-earnings ratio of -166.58 and a beta of 0.27. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.71.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. As a group, equities analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the company. Wall Street Zen raised BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Morgan Stanley increased their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, June 27th. JPMorgan Chase & Co. boosted their price target on shares of BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Royal Bank Of Canada increased their price objective on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a research note on Thursday. Finally, TD Securities reissued a "buy" rating and set a $334.00 target price on shares of BeOne Medicines in a research report on Thursday, April 24th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $330.89.
View Our Latest Stock Report on BeOne Medicines
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONC. Parallel Advisors LLC purchased a new stake in shares of BeOne Medicines during the second quarter valued at approximately $59,000. Aaron Wealth Advisors LLC bought a new position in BeOne Medicines in the 2nd quarter valued at approximately $200,000. Farther Finance Advisors LLC purchased a new stake in BeOne Medicines during the 2nd quarter valued at $39,000. Avanza Fonder AB bought a new stake in shares of BeOne Medicines in the 2nd quarter worth $199,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of BeOne Medicines in the second quarter worth $3,491,000. Institutional investors own 48.55% of the company's stock.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Featured Articles
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
